Atlas Trials

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Clinical trial NCT05640791 · RECRUITING

Trial details

NCT number
NCT05640791
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Biliary Tract Cancer
Start date
2023-01-12
Primary completion
2023-12-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.